Alma Tostmann

Dr. Alma Tostmann


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2007 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
ATAlma Tostmann
Alma Tostmann
MBMartin J Boeree
Martin J Boeree
RARob E Aarnoutse
Rob E Aarnoutse
WLWiel C M De Lange
Wiel C M De Lange
AVAndre J A M Van Der Ven
Andre J A M Van Der Ven
RDRichard Dekhuijzen
Richard Dekhuijzen

1 November 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ATAlma Tostmann
Alma Tostmann
SKSandra V. Kik
Sandra V. Kik
NKNico A. Kalisvaart
Nico A. Kalisvaart
MSMaruschka M. Sebek
Maruschka M. Sebek
SVSuzanne Verver
Suzanne Verver
DSDick van Soolingen
Dick van Soolingen
Background. Sputum smear microscopy is commonly used for diagnosing tuberculosis (TB). Although patients with sputum smear–negative TB are less infec

23 April 2020 in Eurosurveillance
Verified
Journal Article
Open access
ATAlma Tostmann
Alma Tostmann
JBJohn Bradley
John Bradley
TBTeun Bousema
Teun Bousema
WYWing-Kee Yiek
Wing-Kee Yiek
MHMinke Holwerda
Minke Holwerda
HWHeiman Wertheim
Heiman Wertheim
Healthcare workers (n = 803) with mild symptoms were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (n = 90 positive) and asked to complete a symptom questionnaire. Anosmia, muscle ache, ocular pain, general malaise, headache, extreme tiredness and fever were associated with positivity. A predictive model based on these symptoms showed moderate discriminative value (sensitivity: 91.2%; specificity: 55.6%). While our models would not justify presumptive SARS-CoV-2 diagnosis without molecular confirmation, it can contribute to targeted screening strategies.

15 April 2006 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
JBJ. Teun Bousema
J. Teun Bousema
PSPetra Schneider
Petra Schneider
LGLouis C. Gouagna
Louis C. Gouagna
CDChris J. Drakeley
Chris J. Drakeley
ATAlma Tostmann
Alma Tostmann
RSRobert W. Sauerwein
Robert W. Sauerwein
BackgroundArtemisinin-based combination therapy (ACT) reduces microscopically confirmed gametocytemia and mosquito infection. However, molecular tech

10 June 2017 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
JHJoost Hopman
Joost Hopman
ATAlma Tostmann
Alma Tostmann
HWHeiman Wertheim
Heiman Wertheim
MBMaria Bos
Maria Bos
EKEva Kolwijck
Eva Kolwijck
HHHans Vd Hoeven
Hans Vd Hoeven
Sinks in patient rooms are associated with hospital-acquired infections. The aim of this study was to evaluate the effect of removal of sinks from the Intensive Care Unit (ICU) patient rooms and the introduction of ‘water-free’ patient care on gram-negative bacilli colonization rates. We conducted a 2-year pre/post quasi-experimental study that compared monthly gram-negative bacilli colonization rates pre- and post-intervention using segmented regression analysis of interrupted time series data. Five ICUs of a tertiary care medical center were included. Participants were all patients of 18 years and older admitted to our ICUs for at least 48 h who also received selective digestive tract decontamination during the twelve month pre-intervention or the twelve month post-intervention period. The effect of sink removal and the introduction of ‘water-free’ patient care on colonization rates with gram-negative bacilli was evaluated. The main outcome of this study was the monthly colonization rate with gram-negative bacilli (GNB). Yeast colonization rates were used as a ‘negative control’. In addition, colonization rates were calculated for first positive culture results from cultures taken ≥3, ≥5, ≥7, ≥10 and ≥14 days after ICU-admission, rate ratios (RR) were calculated and differences tested with chi-squared tests. In the pre-intervention period, 1496 patients (9153 admission days) and in the post-intervention period 1444 patients (9044 admission days) were included. Segmented regression analysis showed that the intervention was followed by a statistically significant immediate reduction in GNB colonization in absence of a pre or post intervention trend in GNB colonization. The overall GNB colonization rate dropped from 26.3 to 21.6 GNB/1000 ICU admission days (colonization rate ratio 0.82; 95%CI 0.67–0.99; P = 0.02). The reduction in GNB colonization rate became more pronounced in patients with a longer ICU-Length of Stay (LOS): from a 1.22-fold reduction (≥2 days), to a 1.6-fold (≥5 days; P = 0.002), 2.5-fold (for ≥10 days; P < 0.001) to a 3.6-fold (≥14 days; P < 0.001) reduction. Removal of sinks from patient rooms and introduction of a method of ‘water-free’ patient care is associated with a significant reduction of patient colonization with GNB, especially in patients with a longer ICU length of stay.

26 April 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
KSK E Stott
K E Stott
HPH Pertinez
H Pertinez
MSM G G Sturkenboom
M G G Sturkenboom
MBM J Boeree
M J Boeree
RAR Aarnoutse
R Aarnoutse
GDG Davies
G Davies
The objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK) of orally administered rifampicin, to derive summary estimates of rifampicin PK parameters at standard dosages and to compare these with summary estimates for higher dosages. A systematic search was performed for studies of rifampicin PK published in the English language up to May 2017. Data describing the Cmax and AUC were extracted. Meta-analysis provided summary estimates for PK parameter estimates at standard rifampicin dosages. Heterogeneity was assessed by estimation of the I2 statistic and visual inspection of forest plots. Summary AUC estimates at standard and higher dosages were compared graphically and contextualized using preclinical pharmacodynamic (PD) data. Substantial heterogeneity in PK parameters was evident and upheld in meta-regression. Treatment duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L (SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mg·h/L (SEM 2.60) and 38.73 mg·h/L (SEM 4.33) after single and steady-state dosing, respectively. Rifampicin dosages of at least 25 mg/kg are required to achieve plasma PK/PD targets defined in preclinical studies. Vast inter-study heterogeneity exists in rifampicin PK parameter estimates. This is not explained by the available modifying variables. The recommended dosage of rifampicin should be increased to improve efficacy. This study provides an important point of reference for understanding rifampicin PK at standard dosages as efforts to explore higher dosing strategies continue in this field.